香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容 而引致的任何損失承擔任何責任。 Modern Chinese Medicine Group Co., Ltd. 現 代 中 藥 集 團 有 限 公 司 （ 於 開 曼 群 島 註 冊 成 立 之 有 限 公 司 ） （股份代號：1643） 截至2025年6月30日止六個月之中期業績公告 財務摘要 現代中藥集團有限公司（「本公司」，連同其附屬公司統稱為「本集團」）董事（「董事」）會（「董事會」）謹 此於下文載列本公司截至2025年6月30日止六個月（「本期間」）的未經審核簡明綜合業績概要連同截至 2024年6月30日止六個月（「上同期」）的比較數字。 - 1 - • 收益由上同期的約人民幣76.6百萬元減少至本期間的約人民幣64.8百萬元，跌幅約15.4%。 • 毛利由上同期的約人民幣21.7百萬元減少至本期間的約人民幣16.2百萬元，跌幅約25.3%。 • 本公司擁有人應佔盈利本期間為人民幣2.5百萬元，而上同期則錄得虧損人民幣6.9 ...

Core Viewpoint - Modern Chinese Medicine Group (01643) expects to achieve a profit attributable to equity holders of no less than RMB 2 million for the six months ending June 30, 2025, compared to a loss of approximately RMB 6.9 million for the six months ending June 30, 2024 [1] Financial Performance - The company anticipates a turnaround from loss to profit primarily due to a significant reduction in losses from the disposal of properties, plants, and equipment [1] - For the six months ending June 30, 2024, the company incurred substantial losses from the disposal of properties, plants, and equipment due to the demolition of the formulation workshop [1] Revenue Outlook - Despite the expected profit, the company's revenue is projected to decrease by 15% to 20% compared to the six months ending June 30, 2024 [1] - The board attributes the revenue decline to intense industry competition [1]

Core Viewpoint - Modern Chinese Medicine Group (01643) expects to achieve a profit attributable to equity holders of no less than RMB 2 million for the six months ending June 30, 2025, compared to a loss of approximately RMB 6.9 million for the six months ending June 30, 2024 [1] Company Performance - The board believes the turnaround from loss to profit is primarily due to a significant reduction in losses from the disposal of properties, plants, and equipment [1] - For the six months ending June 30, 2024, the company incurred substantial losses from the disposal of properties, plants, and equipment due to the demolition of the formulation workshop [1] Revenue Outlook - Despite the expected profit, the company's revenue is projected to decrease by 15% to 20% compared to the six months ending June 30, 2024 [1] - The board attributes the revenue decline to intense industry competition [1]

格隆汇8月15日丨现代中药集团(01643.HK)公布，集团预计截至2025年6月30日止六个月录得公司股权持 有人应占溢利不少于人民币2.0百万元，而截至2024年6月30日止六个月则录得亏损约人民币6.9百万元。 董事会认为业绩由亏转盈主要由于处置物业、厂房及设备的亏损大幅减少。截至2024年6月30日止六个 月，由于拆除制剂车间，集团录得了巨额处置物业、厂房及设备的亏损。尽管如此，本期间的收入较截 至2024年6月30日止六个月预计将减少15%至20%。董事会认为，收入减少主要由于行业竞争激烈。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 - 1 - 1643 內幕消息公告 正面盈利預警 本公告乃由現代中藥集團有限公司（「本公司」，連同其附屬公司，統稱「本集團」）根據香港聯合 交易所有限公司證券上市規則（「上市規則」）第13.09條以及香港法例第571章證券及期貨條例第 XIVA部項下的內幕消息條文（定義見上市規則）而作出。 本公司董事（分別為「董事」及「董事會」）謹此知會本公司股東（「股東」）及有意投資者，根據對董 事會目前可得的最新資料及本集團截至2025年6月30日止六個月（「本期間」）的未經審核綜合管 理賬目作出的初步評估，本集團預期於本期間錄得本公司股權持有人應佔溢利不少於人民幣 2.0百萬元，而截至2024年6月30日止六個月則錄得虧損約人民幣6.9百萬元。董事會認為業績由 虧轉盈主要由於處置物業、廠房及設備之虧損大幅減少。截至2024年6月30日止六個月，由於 拆除製劑車間，本集團錄得了巨額處置物業、廠房及設備之虧損。 儘管 ...

格隆汇8月15日丨现代中药集团(01643.HK)宣布，本公司将于2025年8月29日（星期五）举行董事会会 议，其中议程包括考虑及批准本公司及其附属公司截至2025年6月30日止六个月的中期业绩及其公告以 供发布及考虑派发中期股息的建议（如有）。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Modern Chinese Medicine Group Co., Ltd. 1643 董事會會議召開日期 現代中藥集團有限公司（「本公司」）之董事會（「董事會」）謹此宣佈，本公司將於2025年8月29日 （星期五）舉行董事會會議，其中議程包括考慮及批准本公司及其附屬公司截至2025年6月30日 止六個月之中期業績及其公告以供發佈及考慮派發中期股息之建議（如有）。 承董事會命 現代中藥集團有限公司 執行董事 張宏麗 香港，2025年8月15日 於本公告日期，董事會成員包括三名執行董事，分別為孫新磊女士、張宏麗女士及賈豔茹女 士；及三名獨立非執行董事，分別為劉淩女士、梁子榮先生及黃志堅先生。 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 重新提交 致：香港交易及結算所有限公司 公司名稱: 現代中藥集團有限公司 (於開曼群島註冊成立的有限公司) 呈交日期: 2025年8月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01643 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 現代中藥集團有限公司 (於開曼群島註冊成立的有限公司) 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01643 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 HKD | | 100,000,000 | 本 ...

Financial Performance - For the fiscal year ending December 31, 2024, the company's revenue and net profit were approximately RMB 214.1 million and RMB 9.7 million, representing a decrease of 37.8% and 80.0% respectively compared to the fiscal year ending December 31, 2023[7]. - The company's sales revenue in Northeast China for the fiscal year 2024 was approximately RMB 114.9 million, a decrease of about 38.9%, accounting for over 53.7% of total revenue[8]. - The group recorded revenue of approximately RMB 214.1 million for the fiscal year 2024, a decrease of about RMB 130 million or 37.8% compared to 2023, primarily due to temporary production stoppage for maintenance work[18]. - The overall gross margin decreased from approximately 30.3% in 2023 to about 25.8% in 2024, mainly due to rising raw material costs and fixed cost absorption during the production stoppage[20]. - Selling and distribution expenses decreased by approximately 8.6% to about RMB 22.3 million in 2024 from RMB 24.4 million in 2023, primarily due to reduced transportation costs[21]. - Cash generated from operating activities significantly increased to approximately RMB 59.0 million in 2024 from RMB 8.5 million in 2023, mainly due to a substantial increase in cash inflow from working capital[25]. - Capital expenditures for 2024 were approximately RMB 116.7 million, significantly higher than RMB 13.4 million in 2023, primarily related to the purchase of properties, plants, and machinery[32]. Market and Product Development - The company currently has around 60 types of traditional Chinese medicine products, with major products including various herbal capsules and pills aimed at treating conditions related to energy, cardiovascular health, digestive issues, and gynecological symptoms[8]. - The Chinese traditional medicine market is expected to continue growing in 2025, driven by increasing consumer demand and government support for traditional medicine policies[9]. - The company plans to enhance its product portfolio through ongoing innovation and research and development, aiming to create more value for shareholders[11]. - The introduction of new technologies and equipment in the production process is expected to improve product quality and production efficiency[9]. - The government is increasingly emphasizing the importance of traditional Chinese medicine, which is expected to enhance the competitiveness of traditional Chinese medicine products in the international market[9]. Corporate Governance - The company has adopted the principles and code provisions of the Corporate Governance Code as the basis for its corporate governance practices[57]. - The board held two regular meetings in 2024, discussing and making decisions on all significant matters related to the group's business activities and operations[57]. - The company is committed to reviewing and monitoring its corporate governance practices to ensure compliance with the Corporate Governance Code[59]. - The board is responsible for the development direction and control of the company's business, formulating policies, strategies, and plans to create value for shareholders[61]. - The company emphasizes the importance of good corporate governance for its sustainable development[57]. Shareholder Communication and Investor Relations - The company emphasizes effective communication with shareholders to enhance investor relations and ensure transparency in business performance and strategies[107]. - The company has established a shareholder communication policy to promote effective engagement and empower shareholders to exercise their rights[108]. - The company has maintained regular communication with institutional investors and analysts to keep them informed of its developments[107]. Environmental, Social, and Governance (ESG) Initiatives - The ESG report covers the company's performance in environmental, social, and governance aspects for the reporting period from January 1, 2024, to December 31, 2024[118]. - The company is committed to sustainable development and has conducted stakeholder engagement to identify key concerns in ESG matters[119]. - The company has established an environmental management system to identify, monitor, and reduce environmental risks[125]. - The company complies with pollution discharge regulations in Hebei Province, China, and has not encountered any significant violations of environmental laws during the reporting period[125]. - The company has obtained pollution discharge permits for all production facilities and has implemented pollution control systems to monitor emission levels[127]. Employee and Workplace Safety - The company has established a health and safety environment, with no recorded work-related fatalities or lost workdays due to injuries in the past three years[156]. - The company emphasizes mental health, providing counseling services and promoting work-life balance through various activities[156]. - The company has a zero-tolerance policy for harassment and discrimination, ensuring a safe and inclusive work environment[162]. - The company has developed emergency plans and conducts regular reviews to maintain workplace safety and effectiveness[155]. Supply Chain Management - The company has a total of 29 approved suppliers across various regions in China, ensuring a stable supply of raw materials[168]. - The company conducts regular reviews of suppliers' production sites to ensure compliance with quality and environmental regulations[168]. - The company has established a quality management system that adheres to GMP standards, managing all stages of the production process[173]. - The company has implemented a supplier classification system to allocate resources effectively, focusing on quality, environmental impact, and compliance[166]. Community Engagement and Corporate Social Responsibility - The group promotes a culture of giving back to the community, encouraging employee participation in charitable activities[182]. - The company is committed to community investment, focusing on areas such as education and health[191]. - The group aims to enhance efforts in various corporate social responsibility areas, including greenhouse gas reduction and employee development and training opportunities[199].